Related Experiment Videos
[Interactions between the human immunodeficiency virus and hepatitis C virus]
1Unité d'hépatologie, hôpital Necker, Paris, France.
La Revue De Medecine Interne
|January 15, 1999
Summary
Hepatitis C virus (HCV) infection affects 9% of human immunodeficiency virus (HIV)-infected individuals, worsening liver disease. Combined therapies show promise for treating HCV in HIV patients.
Area of Science:
- Virology
- Immunology
- Hepatology
Context:
- Hepatitis C virus (HCV) infection is prevalent in 9% of human immunodeficiency virus (HIV)-infected individuals.
- HIV infection exacerbates HCV replication, leading to more severe liver damage and faster cirrhosis progression.
- Understanding the interplay between HCV and HIV is crucial for managing coinfection.
Purpose:
- To evaluate the reciprocal interactions between HCV and HIV.
- To highlight the need for early diagnosis and treatment of HCV in HIV-infected patients.
- To assess the impact of combined therapies on HCV treatment outcomes.
Summary:
- HCV infection in HIV-positive individuals often results in chronic hepatitis and persistent viremia.
- HIV accelerates HCV replication, increasing the risk of severe liver lesions and cirrhosis.
- Current treatment options like interferon alpha have limited long-term efficacy, necessitating novel therapeutic strategies.
Impact:
- Combined therapies, particularly those including ribavirin, may improve long-term response rates.
- The influence of antiretroviral triple therapy and immune restoration on HCV natural history requires further investigation.
- Future research should focus on assessing how these advancements alter HCV infection outcomes in coinfected patients.